Irmukin 80mg Tablets

Introduction to Irmukin 80mg Tablets

Irmukin 80mg, manufactured by Genvio Pharma Limited, contains Osimertinib, a third-generation EGFR tyrosine kinase inhibitor. This medication is specifically designed for treating non-small cell lung cancer (NSCLC) in patients with EGFR mutations. Irmukin works by blocking the EGFR  that drives uncontrolled cancer cell growth, slowing down or halting the progression of the disease.

It is used both as a first-line therapy for metastatic NSCLC and in cases where the cancer has developed resistance to previous EGFR-targeted treatments. Patients must take Irmukin as directed by their healthcare provider for optimal results.